Femasys (FEMY) Total Non-Current Liabilities (2020 - 2026)
Femasys' (FEMY) quarterly Total Non-Current Liabilities came in at $6.1 million in Q1 2026, up 320.16% YoY from $1.4 million in Q1 2025, and down 46.07% on a QoQ basis from $11.2 million in Q4 2025.
Femasys (FEMY) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Femasys (FEMY) has 7 years of Total Non-Current Liabilities data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 320.16% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 320.16% YoY) and the FY2025 annual result came in at $11.2 million, up 620.2% from the prior year.
- Total Non-Current Liabilities fell to $6.1 million in Q1 2026, from $11.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $11.2 million in Q4 2025 to a low of $56245.0 in Q2 2023.
- A 5-year average of $3.1 million and a median of $1.4 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 11567.19% — and 2025, when it tumbled 82.33%.
- Tracing FEMY's Total Non-Current Liabilities over 5 years: stood at $125242.0 in 2022, then jumped by 4969.53% to $6.3 million in 2023, then plunged by 75.47% to $1.6 million in 2024, then soared by 620.2% to $11.2 million in 2025, then plunged by 46.07% to $6.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $6.1 million (Q1 2026), $11.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.86 Bn | 129.64 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.40 Bn | 51.53 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.87 Bn | 32.40 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 28.85 Bn | 26.17 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.04 Bn | 24.60 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.35 Bn | 14.94 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.87 Bn | 14.73 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.61 Bn | 11.46 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Femasys | 10.37 Mn | 8.93 Mn | 189,391.00 | 4.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 11.22 Mn |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 6.35 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 56,245.00 |
| Mar 31, 2023 | 98,818.00 |
| Dec 31, 2022 | 125,242.00 |
| Sep 30, 2022 | 217,577.00 |
| Jun 30, 2022 | 318,237.00 |
| Mar 31, 2022 | 407,573.00 |
| Dec 31, 2021 | 552,208.00 |
| Sep 30, 2021 | 690,767.00 |
| Jun 30, 2021 | 788,469.00 |